NYSE:MRKPharmaceuticals
Merck (MRK) Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation
Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are significant highlights. Over the last quarter, Merck's stock price moved up 8%, a positive change in line with the broader market's upward trend of a 16% climb over the year. In parallel, the company's moves, such as share buybacks and potential acquisitions like Verona Pharma, added weight to these...